RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors
2017-01-01 INCORVAIA, Lorena; Passiglia, F.; RIZZO, Sergio; GALVANO, Antonio; LISTI', Angela; Barraco, Nadia; Maragliano, R.; CALO', Valentina; Natoli, C.; CIACCIO, Marcello; BAZAN, Viviana; RUSSO, Antonio
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
2022-01-01 Malapelle, Umberto; Passiglia, Francesco
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?
2016-01-01 Passiglia, Francesco; Russo, Antonio
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it
2014-01-01 Rolfo, Christian; Passiglia, Francesco; Castiglia, Marta; Raez, Luis E.; Germonpre, Paul; Gil-Bazo, Ignacio; Zwaenepoel, Karen; De Wilde, Annemieke; Bronte, Giuseppe; Russo, Antonio; Van Meerbeeck, Jan P.; Van Schil, Paul; Pauwels, Patrick
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?
2016-01-01 Bronte, Giuseppe; Passiglia, Francesco; Galvano, Antonio; Russo, Antonio
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
2014-01-01 BRONTE, Giuseppe; Rolfo, C; Giovannetti, E; CICERO, Giuseppe; Pauwels, P; PASSIGLIA, Francesco; CASTIGLIA, Marta; Lo Vullo, F; FIORENTINO, Eugenio; Van Meerbeeck, J; RUSSO, Antonio; RIZZO, Sergio
Cancer and the microbiome: Potential applications as new tumor biomarker
2015-01-01 Shahanavaj, Khan; Gil-Bazo, Ignacio; Castiglia, Marta; Bronte, Giuseppe; Passiglia, Francesco; Carreca, Anna P; Del Pozo, José Luis; Russo, Antonio; Peeters, Marc; Rolfo, Christian
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors
2018-01-01 Bronte, Enrico; Bronte, Giuseppe; Novo, Giuseppina; Rinaldi, Gaetana; Bronte, Fabrizio; Passiglia, Francesco; Russo, Antonio
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery
2022-01-01 Bungaro M.; Passiglia F.; Scagliotti G.V.
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer
2021-01-01 Remon J.; Pignataro D.; Novello S.; Passiglia F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors | 2017 | INCORVAIA, Lorena; Passiglia, F.; RIZZO, Sergio; GALVANO, Antonio; LISTI', Angela; Barraco, Nadia; Maragliano, R.; CALO', Valentina; Natoli, C.; CIACCIO, Marcello; BAZAN, Viviana; RUSSO, Antonio | |
| A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib | 2022 | Malapelle, Umberto; Passiglia, Francesco | |
| Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients? | 2016 | Passiglia, Francesco; Russo, Antonio | |
| ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it | 2014 | Rolfo, Christian; Passiglia, Francesco; Castiglia, Marta; Raez, Luis E.; Germonpre, Paul; Gil-Bazo, Ignacio; Zwaenepoel, Karen; De Wilde, Annemieke; Bronte, Giuseppe; Russo, Antonio; Van Meerbeeck, Jan P.; Van Schil, Paul; Pauwels, Patrick | |
| Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? | 2016 | Bronte, Giuseppe; Passiglia, Francesco; Galvano, Antonio; Russo, Antonio | |
| Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects | 2014 | BRONTE, Giuseppe; Rolfo, C; Giovannetti, E; CICERO, Giuseppe; Pauwels, P; PASSIGLIA, Francesco; CASTIGLIA, Marta; Lo Vullo, F; FIORENTINO, Eugenio; Van Meerbeeck, J; RUSSO, Antonio; RIZZO, Sergio | |
| Cancer and the microbiome: Potential applications as new tumor biomarker | 2015 | Shahanavaj, Khan; Gil-Bazo, Ignacio; Castiglia, Marta; Bronte, Giuseppe; Passiglia, Francesco; Carreca, Anna P; Del Pozo, José Luis; Russo, Antonio; Peeters, Marc; Rolfo, Christian | |
| Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors | 2018 | Bronte, Enrico; Bronte, Giuseppe; Novo, Giuseppina; Rinaldi, Gaetana; Bronte, Fabrizio; Passiglia, Francesco; Russo, Antonio | |
| COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery | 2022 | Bungaro M.; Passiglia F.; Scagliotti G.V. | |
| Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer | 2021 | Remon J.; Pignataro D.; Novello S.; Passiglia F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 03-CONTRIBUTO IN RIVISTA 58
- 03-CONTRIBUTO IN RIVISTA::03B-Rev... 58
Data di pubblicazione
- 2023 6
- 2022 7
- 2021 5
- 2020 4
- 2018 7
- 2017 6
- 2016 6
- 2015 7
- 2014 9
- 2013 1
Rivista
- CRITICAL REVIEWS IN ONCOLOGY HEMA... 6
- CANCER TREATMENT REVIEWS 5
- EXPERT OPINION ON BIOLOGICAL THERAPY 3
- JOURNAL OF THORACIC ONCOLOGY 3
- TRANSLATIONAL LUNG CANCER RESEARCH 3
- EXPERT OPINION ON INVESTIGATIONAL... 2
- EXPERT REVIEW OF ANTICANCER THERAPY 2
- ONCOTARGET 2
- TRANSLATIONAL CANCER RESEARCH 2
- ANALYTICAL CELLULAR PATHOLOGY 1
Keyword
- Humans 12
- NSCLC 10
- Oncology 9
- Lung Neoplasms 7
- Pharmacology 7
- EGFR 5
- Immunotherapy 5
- Non-small cell lung cancer 5
- Pharmacology (medical) 5
- Resistance 5
Lingua
- eng 58
Accesso al fulltext
- reserved 35
- open 19
- no fulltext 4